Governments should license publicly funded drug patents to competitors when prices are unaffordable

Drug pricing and affordability, FDA drug approvals, clinical trial design, drug shortages, insurer coverage, pharmaceutical regulation, and medication access.

Medicaid, Medicare, ACA, NHS, insurance coverage, prior authorization, healthcare workforce, and access disparities.

Medicare Part B/D, Medicare Advantage, IRA drug negotiations, 340B, most-favored-nation pricing, and federal drug pricing policy.

Medicaid cuts, funding freezes, state waivers, directed payments, CHIP, and state-level healthcare access policies.

Medical debt, out-of-pocket costs, voter concerns, racial disparities, rural access, and international healthcare access.

Nurse shortages, telehealth expansion, NHS workforce, hospital consolidation, and psychiatric care access.

ACA enrollment, premiums, marketplace cancellations, Essential Plan, uninsured rate, and insurance regulation.

Drug pricing policy, insurance prior authorization, and essential drug shortages affecting medication affordability and access.

Substances used for treatment, prevention, or diagnosis of disease.